Stout NL, Wagner SS. Antineoplastic therapy side effects and polypharmacy in older adults with cancer. Top Geriatr Rehabil. 2019;35(1):15–30. https://doi.org/10.1097/TGR.0000000000000212.
Article PubMed PubMed Central Google Scholar
2.Sohail MF, Rehman M, Sarwar HS, Naveed S, Salman O, Bukhari NI, et al. Advancements in the oral delivery of docetaxel: challenges, current state-of-the-art and future trends. Int J Nanomedicine. 2018;13:3145–61. https://doi.org/10.2147/ijn.S164518.
CAS Article PubMed PubMed Central Google Scholar
3.Ashtarinezhad A, Panahyab A, Vatanpour H, Shirazi F. FTIR determination of miconazole effects on mice fetus brain tissue. Iranian J Pharm Sci. 2014;10(2):79–84.
4.Thirumaran R, Prendergast GC, Gilman PB. Chapter 7 - Cytotoxic chemotherapy in clinical treatment of cancer. In: Prendergast GC, Jaffee EM, editors. Cancer Immunotherapy. Burlington: Academic Press; 2007. p. 101–16.
5.Fletcher DA, Mullins RD. Cell mechanics and the cytoskeleton. Nature. 2010;463(7280):485–92. https://doi.org/10.1038/nature08908.
CAS Article PubMed PubMed Central Google Scholar
6.Oshiro C, Marsh S, McLeod H, Carrillo MW, Klein T, Altman R. Taxane pathway. Pharmacogenet Genomics. 2009;19(12):979–83. https://doi.org/10.1097/FPC.0b013e3283335277.
CAS Article PubMed PubMed Central Google Scholar
7.Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997;57(2):229–33.
8.Mackler NJ, Pienta KJ. Drug insight: use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol. 2005;2(2):92–100.
9.Eftekhari S, Montazeri H, Tarighi P. Synergistic anti-tumor effects of liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line. European Journal of Pharmacology. 2020;878:173102.
10.Jain S, Spandana G, Agrawal AK, Kushwah V, Thanki K. Enhanced antitumor efficacy and reduced toxicity of docetaxel loaded estradiol functionalized stealth polymeric nanoparticles. Mol Pharm. 2015;12(11):3871–84.
11.Taheri-Ledari R, Zhang W, Radmanesh M, Mirmohammadi SS, Maleki A, Cathcart N, et al. Multi-stimuli nanocomposite therapeutic: docetaxel targeted delivery and synergies in treatment of human breast cancer tumor. Small. 2020;16(41):2002733.
12.Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of taxane resistance. Cancers. 2020;12(11):57. https://doi.org/10.3390/cancers12113323.
13.Nøhr-Nielsen A, Bagger SO, Brünner N, Stenvang J, Lund TM. Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line. European Journal of Pharmaceutical Sciences. 2020;148:105315.
14.Pucci P, Rescigno P, Sumanasuriya S, de Bono J, Crea F. Hypoxia and noncoding RNAs in taxane resistance. Trends Pharmacol Sci. 2018;39(8):695–709. https://doi.org/10.1016/j.tips.2018.05.002.
CAS Article PubMed Google Scholar
15.Guo YF, Zhao S, Qiu HH, Wang T, Zhao YN, Han MH, et al. Shape of nanoparticles as a design parameter to improve docetaxel antitumor efficacy. Bioconjug Chem. 2018;29(4):1302–11. https://doi.org/10.1021/acs.bioconjchem.8b00059.
CAS Article PubMed Google Scholar
16.Panda J, Satapathy BS, Mandal B, Sen R, Mukherjee B, Sarkar R, et al. Anticancer potential of docetaxel-loaded cobalt ferrite nanocarrier: an in vitro study on MCF-7 and MDA-MB-231 cell lines. J Microencapsul. 2021;38(1):36–46. https://doi.org/10.1080/02652048.2020.1842529.
CAS Article PubMed Google Scholar
17.Hu Y, Ran M, Wang B, Lin Y, Cheng Y. Co-delivery of docetaxel and curcumin via nanomicelles for enhancing anti-ovarian cancer treatment. 2020;15:9703-15. https://doi.org/10.2147/ijn.s274083.
18.Dawoud M, Abourehab MA, Abdou R. Monoolein cubic nanoparticles as novel carriers for docetaxel. J Drug Deliv Sci Technol. Part A. 2020;56:101501. https://doi.org/10.1016/j.jddst.2020.101501.
19.Dong Z, Shen Y, Zhao S, Wang X, Han M, Zhao N et al. Influence of hydrophobic chains in nanocarriers on antitumor efficacy of docetaxel nanoparticles. 2020;17(4):1205-14. https://doi.org/10.1021/acs.molpharmaceut.9b01228.
20.Li N, Mai Y, Liu Q, Gou G, Yang J. Docetaxel-loaded D-α-tocopheryl polyethylene glycol-1000 succinate liposomes improve lung cancer chemotherapy and reverse multidrug resistance. Drug Deliv Transl Res. 2021;11(1):131–41. https://doi.org/10.1007/s13346-020-00720-9.
CAS Article PubMed Google Scholar
21.Ding Y, Ding Y, Wang Y, Wang C, Gao M, Xu Y, et al. Soluplus(®)/TPGS mixed micelles for co-delivery of docetaxel and piperine for combination cancer therapy. Pharm Dev Technol. 2020;25(1):107–15. https://doi.org/10.1080/10837450.2019.1679834.
CAS Article PubMed Google Scholar
22.Talkar SS, Kharkar PB, Patravale VB. Docetaxel loaded pomegranate seed oil based nanostructured lipid carriers: a potential alternative to current formulation. AAPS PharmSciTech. 2020;21(8):295. https://doi.org/10.1208/s12249-020-01839-1.
CAS Article PubMed Google Scholar
23.Ghamkhari A, Abbasi F, Abbasi E, Ghorbani M. A novel thermo-responsive system based on β-cyclodextrin-nanocomposite for improving the docetaxel activity. Int J Polym Mater Polym Biomater. 2020:1–11. https://doi.org/10.1080/00914037.2020.1765357.
24.Gong F, Wang R, Zhu Z, Duan J, Teng X, Cui Z-K. Drug-interactive mPEG-b-PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel. Drug Delivery. 2020;27(1):238–47. https://doi.org/10.1080/10717544.2020.1718245.
CAS Article PubMed PubMed Central Google Scholar
25.Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71(8):1185–98. https://doi.org/10.1111/jphp.13098.
CAS Article PubMed Google Scholar
26.He C, Cai P, Li J, Zhang T, Lin L, Abbasi AZ, et al. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer. J Control Release. 2017;246:98–109. https://doi.org/10.1016/j.jconrel.2016.12.019.
CAS Article PubMed Google Scholar
27.Gao J, Liu J, Xie F, Lu Y, Yin C, Shen X. Co-delivery of docetaxel and salinomycin to target both breast cancer cells and stem cells by PLGA/TPGS nanoparticles. Int J Nanomedicine. 2019;14:9199–216. https://doi.org/10.2147/IJN.S230376.
CAS Article PubMed PubMed Central Google Scholar
28.Hoang B, Ernsting MJ, Roy A, Murakami M, Undzys E, Li SD. Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism. Biomaterials. 2015;59:66–76. https://doi.org/10.1016/j.biomaterials.2015.04.032.
CAS Article PubMed PubMed Central Google Scholar
29.Vardhan H, Mittal P, Adena SK, Mishra B. Long-circulating polyhydroxybutyrate-co-hydroxyvalerate nanoparticles for tumor targeted docetaxel delivery: formulation, optimization and in vitro characterization. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences. 2017;99:85-94. https://doi.org/10.1016/j.ejps.2016.12.007.
30.Marcinkowska M, Stanczyk M, Janaszewska A, Gajek A, Ksiezak M, Dzialak P, et al. Molecular mechanisms of antitumor activity of PAMAM dendrimer conjugates with anticancer drugs and a monoclonal antibody. Polymers. 2019;11(9):16. https://doi.org/10.3390/polym11091422.
31.Ashrafizadeh M, Ahmadi Z, Mohamadi N, Zarrabi A, Abasi S, Dehghannoudeh G, et al. Chitosan-based advanced materials for docetaxel and paclitaxel delivery: recent advances and future directions in cancer theranostics. Int J Biol Macromol. 2020;145:282–300. https://doi.org/10.1016/j.ijbiomac.2019.12.145.
CAS Article PubMed Google Scholar
32.Mirzaie ZH, Irani S, Mirfakhraie R, Atyabi SM, Dinarvand M, Dinarvand R, et al. Docetaxel-chitosan nanoparticles for breast cancer treatment: cell viability and gene expression study. Chem Biol Drug Des. 2016;88(6):850–8. https://doi.org/10.1111/cbdd.12814.
CAS Article PubMed Google Scholar
33.Wang H, Xu Y, Zhou X. Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation. Int J Mol Sci. 2014;15(3):3519–32. https://doi.org/10.3390/ijms15033519.
CAS Article PubMed PubMed Central Google Scholar
34.Lee E, Kim H, Lee I-H, Jon S. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release. 2009;140(2):79–85. https://doi.org/10.1016/j.jconrel.2009.08.014.
CAS Article PubMed Google Scholar
35.Hwang H-Y, Kim I-S, Kwon IC, Kim Y-H. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2008;128(1):23–31. https://doi.org/10.1016/j.jconrel.2008.02.003.
CAS Article PubMed Google Scholar
36.Mu C-F, Cui F, Yin Y-M, Cho H-J, Kim D-D. Docetaxel-loaded chitosan-cholesterol conjugate-based self-assembled nanoparticles for overcoming multidrug resistance in cancer cells. Pharmaceutics. 2020;12(9):783.
37.Youm I, Agrahari V, Murowchick JB, Youan B-BC. Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells. Pharm Res. 2014;31(9):2439–52.
38.Zhu Z, Li Y, Yang X, Pan W, Pan H. The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles. Pharmacol Res. 2017;126:84–96. https://doi.org/10.1016/j.phrs.2017.07.011.
CAS Article PubMed Google Scholar
39.He L, Shang Z, Liu H, Yuan Z-x. Alginate-based platforms for cancer-targeted drug delivery. Biomed Res Int. 2020;2020:1487259–17. https://doi.org/10.1155/2020/1487259.
CAS Article PubMed PubMed Central Google Scholar
40.Zhang P, Chen L, Zhang Z, Lin L, Li Y. Pharmacokinetics in rats and efficacy in murine ovarian cancer model for solid lipid nanoparticles loading docetaxel. J Nanosci Nanotechnol. 2010;10(11):7541–4. https://doi.org/10.1166/jnn.2010.2819.
CAS Article PubMed Google Scholar
41.da Rocha MCO, da Silva PB, Radicchi MA, Andrade BYG, de Oliveira JV, Venus T, et al. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4 T1 murine mammary carcinoma cells. J Nanobiotechnology. 2020;18(1):43. https://doi.org/10.1186/s12951-020-00604-7.
CAS Article PubMed PubMed Central Google Scholar
42.Kim KS, Youn YS, Bae YH. Immune-triggered cancer treatment by intestinal lymphatic delivery of docetaxel-loaded nanoparticle. Journal of controlled release : official journal of the Controlled Release Society. 2019;311-312:85-95. doi:10.1016/j.jconrel.2019.08.027.
43.Kothari IR, Mazumdar S, Sharma S, Italiya K, Mittal A, Chitkara D. Docetaxel and alpha-lipoic acid co-loaded nanoparticles for cancer therapy. Ther Deliv. 2019;10(4):227–40. https://doi.org/10.4155/tde-2018-0074.
留言 (0)